Table 1.
Participant Demographics and Clinical Information
| Characteristic | FES (N = 43) | HC (N = 24) | ||||||
|---|---|---|---|---|---|---|---|---|
| Mean | SD | N | Mean | SD | N | t/χ2 | P value | |
| Age (y) | 22.92 | 5.04 | 22.29 | 2.86 | t = 0.66 | .51 | ||
| Sex | χ2 = 1.32 | .25 | ||||||
| Males | 31 | 14 | ||||||
| Females | 12 | 10 | ||||||
| IQ | 106.4 | 13.76 | 105.9 | 9.28 | t = 0.15 | .88 | ||
| Number of antipsychotic naive | 15 | |||||||
| BPRS (total) | 46.56 | 8.44 | NA | |||||
| BPRS (psychotic symptoms) | 13.28 | 3.53 | NA | |||||
| BPRS (negative symptoms) | 7.16 | 2.49 | NA | |||||
| Strauss–Carpenter follow-up total score | 12.3 | 2.53 | NA | |||||
| Mean antipsychotic dosage (chlorpromazine equivalent in mg) | 83.72 | 103.08 | NA |
Note: BPRS, Brief Psychiatric Rating Scale; FES, first-episode schizophrenia; HC, healthy control; NA, not available.